689 related articles for article (PubMed ID: 24882567)
21. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
Poulin JM; Bigford GE; Lanctôt KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; Husain MI; Rosenblat JD; Cao X; MacIntosh BJ; Nestor SM
Trials; 2024 Jul; 25(1):441. PubMed ID: 38956594
[TBL] [Abstract][Full Text] [Related]
22. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME
Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319
[TBL] [Abstract][Full Text] [Related]
23. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
[TBL] [Abstract][Full Text] [Related]
24. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects.
Mueller F; Lenz C; Dolder PC; Harder S; Schmid Y; Lang UE; Liechti ME; Borgwardt S
Transl Psychiatry; 2017 Apr; 7(4):e1084. PubMed ID: 28375205
[TBL] [Abstract][Full Text] [Related]
25. Effects of psilocybin on time perception and temporal control of behaviour in humans.
Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
[TBL] [Abstract][Full Text] [Related]
26. Automatic mood-congruent amygdala responses to masked facial expressions in major depression.
Suslow T; Konrad C; Kugel H; Rumstadt D; Zwitserlood P; Schöning S; Ohrmann P; Bauer J; Pyka M; Kersting A; Arolt V; Heindel W; Dannlowski U
Biol Psychiatry; 2010 Jan; 67(2):155-60. PubMed ID: 19748075
[TBL] [Abstract][Full Text] [Related]
27. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
28. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
[TBL] [Abstract][Full Text] [Related]
29. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
[TBL] [Abstract][Full Text] [Related]
30. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
31. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
Bernasconi F; Schmidt A; Pokorny T; Kometer M; Seifritz E; Vollenweider FX
Cereb Cortex; 2014 Dec; 24(12):3221-31. PubMed ID: 23861318
[TBL] [Abstract][Full Text] [Related]
32. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
Gouzoulis-Mayfrank E; Schreckenberger M; Sabri O; Arning C; Thelen B; Spitzer M; Kovar KA; Hermle L; Büll U; Sass H
Neuropsychopharmacology; 1999 Jun; 20(6):565-81. PubMed ID: 10327426
[TBL] [Abstract][Full Text] [Related]
33. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
[TBL] [Abstract][Full Text] [Related]
34. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
[TBL] [Abstract][Full Text] [Related]
35. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
[TBL] [Abstract][Full Text] [Related]
36. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
Carhart-Harris RL; Leech R; Erritzoe D; Williams TM; Stone JM; Evans J; Sharp DJ; Feilding A; Wise RG; Nutt DJ
Schizophr Bull; 2013 Nov; 39(6):1343-51. PubMed ID: 23044373
[TBL] [Abstract][Full Text] [Related]
37. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill--a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive.
Gingnell M; Engman J; Frick A; Moby L; Wikström J; Fredrikson M; Sundström-Poromaa I
Psychoneuroendocrinology; 2013 Jul; 38(7):1133-44. PubMed ID: 23219471
[TBL] [Abstract][Full Text] [Related]
38. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
[TBL] [Abstract][Full Text] [Related]
39. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
40. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
Turton S; Nutt DJ; Carhart-Harris RL
Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
